Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine and Oxybutynin for Symptomatic Snoring
NCT03720353Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atomoxetine, oxybutynin in primary snoring, sponsored by Brigham and Women's Hospital. Started Dec 2018; status: completed.
02
Drugs
atomoxetineoxybutynin
03
Conditions
primary snoring
Beyond the preview
Go deeper on NCT03720353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720353.